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Toxoplasma p n d i i  is among the most common causes of latent 
infection of humans throughout the world. This chronic latent 
infection is associated with cysts of the organism in multiple organs 
and appears to be an active process of cyst disruption and reformation, 
ordinarily unaccompanied by clinical evidence of disease or tissue 
destruction. Immunologically normal individuals with acute acquired 
toxoplasma infection usually have a self-limited clinical course and 
do not require specific treatment directed at the parasite. Both 
humoral and cell-mediated immunity mediate the resistance, 
although the latter appears to play the primary role. Limitation of 
spread and containment of the latent form of the infection is 
compromised when there is a severe defect in the immune system 
and especially in cell-mediated immunity. This is most clearly 
evidenced by the tragic and frequent occurrence of toxoplasinosis in 
individuals with the acquired immunodeficiency syndrome (AIDS), 
The mechanisms by which infection with Exoplasma i s  maintained 
in a quiescent state are incompletely understood. The advent ofAIDS 
and its associated immunologic abnormalities has revealed how 
important a severe disturbance ofT-lymphocyte function is as a factor 
predisposing to developinent of toxoplacniosis in the imniuno- 
compromised host. This i s ,  at least in part, due to an abnormality in 
production of cytokines critical to resistance against this organism. 
Although this has received widespread atteiitioii in the literature, the 
subject of toxoplasmosis in patients who are iiniiiunocompromised 
by other conditions has been relatively neglected in the literature. 
Toxoplasmosis has been found to be associated with a wide variety 
of conditions that result in immunosuppression and has been reported 
to involve nearly every organ system in AIDS and non-AIDS 
imniunoconipromised patients. Clinical syndromes associated with 
toxoplasmosis in iinniunocomproiiiised patients are most frequently 
encephalitis, myocarditis, and pneunionitis. In addition, cases of 
widely disseminated toxoplasnia infection have been described. The 
majority of cases in non-AIDS imrnunocompromised patients have 
occurred in individuals with malignancies, most frequently 
Hodgkin's lymphoma, and in recipients of heart, bone marrow and 
renal transplants. Clearly, toxoplasmosis can be present in the 
iiiiiiiunosuppressed patient without malignancies, including those on 
corticosteroids or with systemic lupus erythematosus. Thus, patients 
on iminunosuppressive regimens niay be seriously predisposed to 
developinent of toxoplasniosis. The unusual occurrence, protean 
clinical manifestations, and devastating consequences of toxo- 
plasniosis in the imniunoconipromised host emphasize the need for 
clinical acunien in the diaposis, management and prevention of this 
disorder. 
Treatment of Toxoplasma infection in pregnant 
women and newborns 
regimens have been used throughout Europe for nearly 30 years. 
Spiraniycin and high-dosc pyriniethamine combined with 
sulfadiazine-folinic acid (P-S-F) have been the d r u g  of choice for 
primary infection in pregnancy, Both regimens have been shown to 
eradicate parasites from infected placentas, while P-S-F has also led 
to a reduction in clinical symptoms of infected infants. 
In a recent multicenter European study a comparison was made 
between 144 seroconverting mothers of whom 119 received prenatal 
treatment, and 125 mothers who were not treated at all. The anti- 
parasitic treatment given in pregnancy had no inipact on the vertical 
transmission rate, but was significantly beneficial in regard to coiii- 
plications of infected infants (OR=0.30) and especially for the 
absence of severe sequelae at 1 year of age (OK=0.14, 95% CI: 
As for postnatal treatment, trials from the USA using continuously 
high doses of P-S-F for a year in symptomatic infants showed a 
striking effect on the ophthalmologic and nephrologic outconie and 
development. In soine countries in Europe, low-dose pyrimethamine 
combined with sulfadoxine (Fansidar) has been used both during 
pregnancy of infected inothers and during the first years of infccted 
infants, yielding a good preventive effect. In future, the new drug  
azithroniycin and ataquovone, which may influence the cystic stage, 
niay prove to be effective. A recent trial of azithroinycin in pregnant 
women will be reported. 
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Viral vectors based on human adeno-associated virus (AAV) have 
become of increasing interest for gene therapy due to several 
advantages over coiiipeting viral vector systems. AAV is non-patho- 
genic, non-immunogenic and infects virtually every cell type tested 
so far, including terminally differentiated or non-dividing cells, 
where the introduced transgene is highly and stably expressed for 
many months. These features have made AAV the preferred vector 
system for applications where stable long-term expression in a 
quiescent cell pool is required and nonspecific iminune stimulation 
should be avoided. 
Unfortunately, AAV vector preparation is very tedious and labonr- 
intensive due to an obligatory DNA transfection step for every round 
of AAV vector production. We have designed a new system for the 
production of rAAV by constructing a helper virus which expresses 
all required AAV helper functions in a single recombinant herpes- 
virus. As a consequence, packaging of rAAV i s  no longer dependent 
on DNA transfection efficiencies but rather relies on simple infection 
of cells to deliver the necessary components. Details of this new 
method for rAAV production will be presented. Use of the strategy 
appears to be a promising step towards large-scale production of 
recombinant AAV vectors to high titers by serial infections. This will 
open the possibility of preparing the enormous vector quantities 
required for clinical applications. 
B. Stray-Pedersen. Gynecolosy/~bs~etr irs  Departmcwr, Natiorial 
Hospital, University of Oslo, Oslo, Norway 
Primary maternal toxoplasina infection can cause congenital 
infection with unpredictable severe sequelae. Different treatment 
